|
Mastocytosis, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In turn, CD25 and FcεRI were found to be expressed in most cases (89% and 92%) in virtually all BMMC (median: 92% and 95%) from both indolent and advanced SM, but with lower/absent levels in a significant fraction of MC leukemia (MCL) and both in MCL and well-differentiated SM (WDSM) patients, respectively.
|
30696068 |
2019 |
|
Mastocytosis, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MCP purity (CD117 and Lin2), maturity (CD34 and FcεRI), interaction receptors and ligands (CD154 and HLA-DR), and SM-specific (CD2 and CD25) markers were measured using flow cytometry.
|
29223146 |
2018 |
|
Mastocytosis, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Morphologically occult involvement of normal-appearing BM by SM will be missed without appropriate clinical suspicion and pathologic evaluation by tryptase and CD25 IHC and KIT D816V mutation analysis.
|
26276780 |
2015 |
|
Mastocytosis, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of CD2- or CD25-positive sMCs was detected in 57.1% of cutaneous mastocytosis (CM) and 90.3% of SM cases (p = 0.008).
|
25402852 |
2014 |
|
Mastocytosis, Systemic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, mutation-related changes of the expression profile can serve as surrogates (besides clustering of mast cells, expression of CD25, and increased release of tryptase) for the presence of the mutation D816 V in tyrosine kinase Kit in patients with systemic mastocytosis according to the WHO criteria.
|
23504229 |
2013 |
|
Mastocytosis, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The increased expression of CD30 associated with absence of CD25 contributes to the diagnosis of WDSM and its distinction from other subtypes of SM.
|
24111625 |
2013 |
|
Mastocytosis, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results show that aberrant expression of CD25 with a FcɛRI(lo), FSC(lo), SSC(lo) and CD45(lo) immature phenotype of BMMC, in the absence of coexisting normal MC in the BM, was associated with multilineage involvement by the D816V KIT mutation, regardless of the diagnostic subtype of the disease (for example, indolent vs aggressive SM), which supports the utility of the immunophenotype of BMMC as a surrogate marker to screen for multilineage KIT mutation in ISM.
|
22051531 |
2012 |
|
Mastocytosis, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
In these patients, MC aberrantly display CD2 and CD25, diagnostic markers of neoplastic MC in all SM variants.
|
21112036 |
2010 |
|
Mastocytosis, Systemic
|
0.100 |
Biomarker
|
disease |
LHGDN |
Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
|
18059223 |
2007 |
|
Mastocytosis, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of tryptase, CD25, CD2 and pSTAT5 was evaluated by immunohistochemistry (IHC) on archival cases of SM and cutaneous mastocytosis (CM). pSTAT5 was detected in 23/23 of SM and 1/9 of CM MC nuclei.23/23 SM had CD25 + MCs.
|
17662084 |
2007 |
|
Mastocytosis, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia.
|
16146815 |
2005 |
|
Mastocytosis, Systemic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because the D816V mutation was detected in the initial bone marrow specimen, strict application of three minor diagnostic criteria (spindling, CD25, D816V) enabled a diagnosis of SM-AML to be confirmed retrospectively in the initial bone marrow tissue.
|
14990611 |
2004 |
|
Mastocytosis, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD25 therefore appears to be a reliable immunohistochemical marker for the discrimination of neoplastic from normal/reactive MCs, with potential as a diagnostic tool in SM.
|
15371947 |
2004 |
|
Mastocytosis, Systemic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although bone marrow biopsies in these patients showed increased numbers of CD25+ mast cells and atypical spindle-shaped mast cells, patients with HES and elevated serum tryptase could be distinguished from patients with systemic mastocytosis and eosinophilia by their clinical manifestations, the absence of mast cell aggregates, the lack of a somatic KIT mutation, and the presence of the recently described fusion of the Fip1-like 1 (FIP1L1) gene to the platelet-derived growth factor receptor alpha gene (PDGFRA).
|
12676775 |
2003 |